Jennifer Frueh

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks

Esther von Stebut, Kristian Reich, Diamant Thaçi et al. · Journal of Investigative Dermatology · 2018 · 223 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*

Kristian Reich, John Sullivan, Petr Arenberger et al. · British Journal of Dermatology · 2020 · 72 citations

Medicine, Dermatology, Pharmacotherapy +17

Secukinumab treatment in new‐onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter <scp>STEPI</scp>n study

Lars Iversen, Liv Eidsmo, Joar Austad et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 53 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from <scp>GESTURE</scp> , a randomized, double‐blind, placebo‐controlled trial

Alice B. Gottlieb, Martijn B. A. van Doorn, John Sullivan et al. · British Journal of Dermatology · 2019 · 40 citations

Medicine, Dermatology, Pharmacotherapy +13

Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the <scp>STEPIn</scp> study

Lars Iversen, Curdin Conrad, Liv Eidsmo et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 35 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13